Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative camrelizumab plus platinum-doublet chemotherapy versus immediate surgery for resectable synchronous multiple primary non-small cell lung cancer
ChiCTR2100050800Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in non-small cell lung cancer (NSCLC) and multiple primary lung cancer (MPLC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Remission rate of postoperative residual multiple pulmonary ground-glass opacity lesions. Started Oct 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)multiple primary lung cancer (MPLC)
Beyond the preview
Go deeper on ChiCTR2100050800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050800.